Register
Register
Register

Thursday, 22 May 2025 | 16:00 - 16:10

An advanced UGent/UZGent platform for Dendritic Cell-based therapy in immune checkpoint-resistant cancers - Karim Vermaelen, Sparxells/Ghent University

Format:In-person

Resistance to today’s standard-of-care cancer immunotherapy i.e. immune checkpoint inhibition (ICI), is a major unmet medical need. We have developed a proprietary mRNA-modified dendritic cell therapy platform, with solid preclinical data showing remarkable activity in a prototypical model of ICI-resistant lung cancer. This platform will be further developed as part of SparXells™, a UGhent spinoff company currently in pre-incorporation phase.